February 24, 2023 -FDA Okays IND Application of BA3182 for Advanced Adenocarcinoma

The FDA has cleared an investigational new drug (IND) application to evaluate BA3182 for the treatment of patients with advanced adenocarcinoma, according to BioAtla, Inc.

As a result of the IND, the company plans to initiate and advance a phase 1 dose-escalation and dose-expansion clinical trial in 2023, which will evaluate the safety, pharmacokinetics, and efficacy of BA3182 in patients with advanced adenocarcinoma.